Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 14:42:101391.
doi: 10.1016/j.conctc.2024.101391. eCollection 2024 Dec.

Defining methods to improve eSource site start-up practices

Affiliations

Defining methods to improve eSource site start-up practices

Amy E Cramer et al. Contemp Clin Trials Commun. .

Abstract

Background: eSource software that transfers patient electronic health record data into a clinical trial electronic case report form holds promise for increasing data quality while reducing data collection, monitoring and source document verification costs. Integrating eSource into multicenter clinical trial start-up procedures could facilitate the use of eSource technologies in clinical trials.

Methods: We conducted a qualitative integrative analysis to identify eSource site start-up key steps, challenges that might occur in executing those steps, and potential solutions to those challenges. We then conducted a value analysis to determine the challenges and solutions with the greatest impacts for eSource implementation teams.

Results: There were 16 workshop participants: 10 pharmaceutical sponsor, 3 academic site, and 1 eSource vendor representative. Participants identified 36 Site Start-Up Key Steps, 11 Site Start-Up Challenges, and 14 Site Start-Up Solutions for eSource-enabled studies. Participants also identified 77 potential impacts of the Challenges upon the Site Start-Up Key Steps and 70 ways in which the Solutions might impact Site Start-Up Challenges. The most important Challenges were: [1] not being able to identify a site eSource champion and [2] not agreeing on an eSource approach. The most important Solutions were: [1] eSource vendors accepting electronic data in the Health Level 7 Fast Healthcare Interoperability Resources (HL7® FHIR®) standard, [2] creating standard content for eSource-related legal documents, and [3] creating a common eSource site readiness checklist.

Conclusions: Site start-up for eSource-enabled multi-center clinical trials is a complex socio-technical problem. This study's Start-Up Solutions provide initial steps for scalable eSource implementation.

Keywords: Clinical research; Clinical trial; Electronic data capture; Electronic health records; Health information technology; eSource.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Amy E. Cramer: Employment, Johnson & Johnson Innovative Medicine. Linda S. King: Employment, Astellas Pharma. Michael T. Buckley: Employment, Memorial Sloan Kettering Cancer Center. Peter Casteleyn: Employment, Johnson & Johnson Innovative Medicine. Cory Ennis: Employment: Duke University School of Medicine. Muayad Hamidi: Employment: UT Health San Antonio. Gonçalo M. C. Rodrigues: Employment, Janssen-Cilag. Denise C. Snyder: Employment, Duke University School of Medicine. Aruna Vattikola: Employment, Merck & Co., Inc. Eric L. Eisenstein: I have nothing to declare.

Update of

References

    1. Getz K.A., Campo R.A. New benchmarks characterizing growth in protocol design complexity. Ther Innov Regul Sci. 2018;52(1):22–28. - PubMed
    1. Getz K.A., Campo R.A. Trial watch: trends in clinical trial design complexity. Nat. Rev. Drug Discov. 2017;16(5):307. - PubMed
    1. DiMasi J.A., Grabowski H.G., Hansen R.W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 2016;47:20–33. - PubMed
    1. Wouters O.J., McKee M., Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844–853. - PMC - PubMed
    1. Eisenstein E.L., Lemons P.W., 2nd, Tardiff B.E., et al. Reducing the costs of phase III cardiovascular clinical trials. Am. Heart J. 2005;149(3):482–488. - PubMed

LinkOut - more resources